These cumulative responder cases strongly suggest the potential therapeutic benefits of BRAF/MEK inhibition in BRAF p.V600E-mutated ameloblastoma (note: such combination is FDA-approved for BRAF p.V600E-mutated thyroid cancer and melanoma). The gene discussed is BRAF; the disease is melanoma.